Medroxyprogesterone (map) in massive doses in oncology: effects of treatment on the ECG in a group of patients with advanced breast carcinoma
Pannuti, F.; Pollutri, E.; Martoni, A.; Camera, P.; Lenaz, G.R.
Bollettino della Societa Italiana di Biologia Sperimentale 50(9): 557-561
1974
ISSN/ISBN: 0037-8771 PMID: 4447750 Document Number: 70380
Document emailed within 1 workday
Related Documents
Pannuti, F. 1977: Modern prospects in the treatment of cancer of the breast and its metastasis. Medroxyprogesterone in massive doses as an alternative to polychemotherapy Minerva Chirurgica 32(19): 1211-1220Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D. 1982: Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages Minerva Ginecologica 34(11): 977-979
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P. 1984: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323
Koeppler, H.; Duru, M.; Grundheber, M.; Heymanns, J.; Jacobs, G.; Pandorf, A.; Rendenbach, B.; Schimke, J.; Weide, R. 2004: Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices Journal of Supportive Oncology 2(2): 159-163
Taylor, S.A.; Von Hoff, D.D.; Baker, L.H.; Balcerzak, S.P. 1984: Phase Ii clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study Cancer Treatment Reports 68(6): 919-920
Samal, B.; Jones, S.; Brownlee, R.W.; Morrison, F.; Hoogstraten, B.; Caoili, E.; Baker, L. 1978: Chromomycin A3 for advanced breast cancer: a Southwest Oncology Group study Cancer Treatment Reports 62(1): 19-22
Sledge, G.W.; Robert, N.; Sparano, J.A.; Cogleigh, M.; Goldstein, L.J.; Neuberg, D.; Rowinsky, E.; Baughman, C.; McCaskill-Stevens, W. 1995: Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer Seminars in Oncology 22(3 Suppl 6: 105-108
Sledge, G.W.; Robert, N.; Sparano, J.A.; Cobeligh, M.; Goldstein, L.J.; Neuberg, D.; Rowinsky, E.; Baughman, C.; McCaskill-Stevens, W. 1994: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience Seminars in Oncology 21(5 Suppl 8: 15-18
Rafla, S.; Johnson, R. 1974: The treatment of advanced prostatic carcinoma with medroxyprogesterone Current Therapeutic Research 16(4): 261-267
Trump, D.L.; Elson, P.J.; Borden, E.C.; Harris, J.E.; Tuttle, R.L.; Whisnant, J.K.; Oken, M.M.; Carignan, J.R.; Ruckdeschel, J.C.; Davis, T.E. 1987: High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study Cancer Treatment Reports 71(2): 165-169
Kochnowski, G.; Rozek, G.; Wisńiewski, J. 1976: Early results of bronchogenic carcinoma treatment with massive doses of cyclophosphamide Wiadomosci Lekarskie 29(4): 270-271
Sadoff, L.; Lusk, W. 1974: The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol T4 LH and testosterone in patients with advanced cancer Obstetrics and Gynecology 43(2): 262-267
Levin, M.; Pandya, K.J.; Khandekar, J.D.; Horton, J.; Glick, J.H.; Bennett, J.M.; Muggia, F.M.; Falkson, G. 1984: Phase Ii study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 68(12): 1511-1512
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
Goldberg, R.M.; Fleming, T.R.; Tangen, C.M.; Moertel, C.G.; Macdonald, J.S.; Haller, D.G.; Laurie, J.A. 1998: Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group Annals of Internal Medicine 129(1): 27-35
Sasagawa, I.; Satomi, S.; Katayama, T. 1989: Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma Gan no Rinsho. Japan Journal of Cancer Clinics 35(6): 767-771
Stehman, F.B.; Blessing, J.A.; Delgado, G.; Louka, M. 1983: Phase Ii evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study Cancer Treatment Reports 67(7-8): 737-738
1974: Assessment of response to treatment in advanced breast cancer. British Breast Group Lancet 2(7871): 38-39
Herrmann, T. 1995: Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Radiation Therapy Oncology Group Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 171(4): 244-245
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362